Metaplastic breast cancer is a rare and aggressive form of breast cancer in which the tumor contains an unusual mix of cell types, including tissue that would not normally be found in the breast, such as bone, cartilage, or cells resembling skin. It accounts for roughly 0.2% of all breast cancers, and most cases test negative for the three receptors that many common breast cancer treatments target: estrogen, progesterone, and HER2.1PubMed Central. Metaplastic Breast Cancer That triple-negative profile, combined with a tendency to resist standard chemotherapy, makes it one of the more difficult breast cancers to treat. Ongoing molecular research is starting to reveal why these tumors behave the way they do and where new treatments might gain a foothold.
How Common It Is and Who It Affects
Although metaplastic breast cancer (often abbreviated MBC or MpBC) is classified as rare, its incidence has been climbing. A population-based analysis found that the age-adjusted incidence per 100,000 people rose from 0.12 to 0.35 over the study period, an annual increase of roughly 3%.2PubMed. Trends of incidence and mortality in metaplastic breast cancer and the effect of contralateral prophylactic mastectomy: A population-based study Whether this reflects a genuine biological increase or simply better recognition and pathological classification is unclear, though improvements in diagnostic criteria probably play a role.
Most patients are diagnosed later in life. A large U.S. study found that the average age at presentation was about 63, with White patients making up roughly three-quarters of cases, Black patients about 16%, and Asian or Pacific Islander patients about 6%.3PubMed Central. Metaplastic Breast Carcinoma in U.S. Population: Racial Disparities, Survival Benefit of Adjuvant Chemoradiation and Future Personalized Treatment with Genomic Landscape Racial disparities in outcomes have been documented, a pattern seen across many breast cancer subtypes, though the small numbers involved in MBC research make it harder to tease apart the relative contributions of biology, access to care, and treatment differences.
The Different Subtypes
One of the defining features of metaplastic breast cancer is its heterogeneity. Under the microscope, the tumor can look dramatically different from one case to the next, and even within a single tumor, multiple tissue types may coexist. The major histologic subtypes include squamous, spindle cell, heterologous mesenchymal (meaning the tumor has produced cartilage, bone, or other connective tissue), and mixed forms that combine several of these elements.4PubMed. Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype
These subtypes are not just academic labels. Survival outcomes differ among them, and emerging research suggests they also differ in their immune environments and molecular profiles. Squamous components, for instance, tend to attract more immune cells than cartilage-producing (chondroid) components, which has implications for whether immunotherapy is likely to help.5PubMed. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components The subtype also matters for diagnosis: a biopsy that captures only the spindle cell portion of a tumor can be hard to distinguish from a non-cancerous condition or a completely different type of tumor.
How It Typically Presents
Metaplastic breast cancers generally show up as rapidly growing masses that you can feel.6PubMed Central. Review of metaplastic carcinoma of the breast: imaging findings and pathologic features Patients often describe a lump that seems to have appeared suddenly or grown quickly over weeks to months, which can be alarming. The tumors tend to be larger at diagnosis than the more common forms of invasive breast cancer, partly because rapid growth catches patients off guard and partly because the imaging appearance can initially be misleading.
In unusual cases, the initial presentation is not even in the breast itself. One documented case involved a 40-year-old woman whose first symptom was a lump in her armpit. Imaging showed no obvious breast tumor, and a biopsy of the armpit mass revealed spindle cells. Only after further workup, including a PET scan, was a primary breast tumor identified. The cancer had already spread to a lymph node before it was detectable as a breast mass.7PubMed Central. Metaplastic breast cancer with a unique presentation and complete response to chemotherapy: a case report While this kind of presentation is uncommon even for MBC, it illustrates how the tumor’s unusual cell types can create diagnostic puzzles.
Why It Is So Hard to Diagnose Before Surgery
One of the most practical problems with metaplastic breast cancer is that it frequently gets misidentified on initial workup. On mammography, these tumors often appear as well-defined, dense masses without the speckled calcifications that raise suspicion for other breast cancers. On ultrasound, they can look like a complex cyst with both solid and fluid-filled areas, features that overlap with both benign lesions and standard invasive ductal carcinoma.8PubMed Central. Multimodality Imaging Findings of Metaplastic Breast Carcinomas: A Report of Five Cases MRI adds detail but can still be ambiguous. The takeaway is that imaging alone rarely clinches the diagnosis.
Core needle biopsy, the standard way to sample a suspicious breast mass, struggles with MBC too. One study found that the diagnostic rate of metaplastic breast cancer on core biopsy was as low as 40%, with most of the remaining cases initially called ordinary ductal carcinoma.9International Journal of Surgery Open. A rare case of metaplastic carcinoma of the breast that could be diagnosed with preoperative core needle biopsy and the improbability of skin invasion The problem is sampling: a needle captures only a sliver of tissue, and if it happens to land in a portion that looks like ordinary cancer (or, worse, like a benign spindle cell proliferation), the metaplastic nature is missed entirely. There is even a documented case where a benign condition called myositis ossificans — a reactive bone-forming lesion — was initially misdiagnosed as metaplastic breast cancer on core biopsy because the biopsy sampled only the cellular, proliferative center of the lesion.10PubMed. Myositis ossificans mimicking metaplastic breast cancer on core needle biopsy Misdiagnosis can run in both directions.
For pathologists trying to confirm the diagnosis, the immunohistochemical marker p63 has proved useful. One study found that p63 was strongly expressed in about 87% of metaplastic carcinomas, including all of those with spindle cell or squamous features, compared to under 1% of non-metaplastic invasive breast cancers.11The American Journal of Surgical Pathology. p63 Expression in Breast Cancer Another study reported somewhat lower sensitivity (around 65%) but similarly high specificity (96%), meaning that when p63 is positive, metaplastic carcinoma is very likely.12PubMed. p63 is useful in the diagnosis of mammary metaplastic carcinomas The variation between studies reflects how different the subtypes can be: p63 reliably marks squamous and spindle elements but is less consistent in tumors that produce cartilage or bone.
Molecular Profile and What Drives These Tumors
Nearly all metaplastic breast cancers are triple-negative, meaning they lack the estrogen receptor, progesterone receptor, and HER2 overexpression that many breast cancer drugs target. In the uncommon cases where HER2 is positive, outcomes appear to be better, likely because HER2-targeted therapy is effective. When hormone receptors are present, they do not seem to carry the same prognostic benefit they confer in ordinary breast cancer.13PubMed Central. Metaplastic Breast Cancer: Current Understanding and Future Directions
What sets MBC apart molecularly from other triple-negative breast cancers is an unusually high rate of mutations in the PI3K signaling pathway. Genomic profiling found that about 61% of metaplastic carcinomas had mutations in PIK3CA or PIK3R1, compared to roughly 14% of other triple-negative cancers — a striking enrichment.14PubMed. Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma A separate analysis also found frequent mutations in Wnt pathway genes (about half of cases) and confirmed high rates of TP53 mutations (around 69%).15Clinical Cancer Research. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas The PI3K pathway helps regulate cell growth and survival, and its overactivation in MBC offers a rationale for targeting it therapeutically.
A biological process called epithelial-to-mesenchymal transition (EMT) also appears central to MBC’s nature. EMT is how cells switch from an organized, tightly adherent state to a looser, more mobile form — a process that normally occurs during wound healing and embryonic development but can be hijacked by cancer. In metaplastic tumors, the mesenchymal components (spindle, cartilage, bone) showed loss of E-cadherin, a protein that glues cells together, and increased expression of ZEB1, a driver of EMT. In the transition zones between epithelial and mesenchymal areas of the same tumor, researchers could literally see E-cadherin dropping and ZEB1 rising.16Modern Pathology. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition This process likely explains why MBC tumors contain such bizarre mixtures of tissue types and may contribute to their resistance to chemotherapy, since mesenchymal-like cancer cells are often harder to kill with standard drugs.
The Immune Landscape and PD-L1
One silver lining in MBC’s otherwise difficult biology is that many of these tumors express PD-L1, a protein that tumors use to evade the immune system and that immunotherapy drugs are designed to block. Using the scoring method from a major triple-negative breast cancer immunotherapy trial, one study found PD-L1 positivity in 95% of metaplastic breast cancers tested.17PubMed Central. PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays A broader comparison found that metaplastic breast cancers were significantly more likely to have PD-L1–positive tumor cells than ordinary triple-negative ductal cancers.18PubMed Central. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1
The immune picture is not uniform across subtypes, though. Squamous components had the highest rates of immune cell infiltration and PD-L1 positivity, while cartilage-producing (matrix-producing) components had the lowest.19PubMed. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components This heterogeneity within a single tumor — one area highly immunogenic, another immunologically “cold” — adds another layer of complexity to treatment planning and may help explain why immunotherapy responses are sometimes dramatic and sometimes disappointing.
Surgery and Radiation
Surgery remains the cornerstone of treatment. Compared to patients with non-metaplastic breast cancers, MBC patients are more likely to undergo mastectomy (about 59% versus 45%).20PubMed Central. Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database Larger tumor size at diagnosis is one reason. For axillary management, sentinel lymph node biopsy with prior ultrasound assessment accurately staged the armpit and provided key prognostic information.21PubMed Central. Management of the axilla in metaplastic breast carcinoma Full axillary lymph node dissection was actually associated with worse survival in a large retrospective study, likely because it was performed more often in patients who already had advanced disease rather than because the surgery itself was harmful.22PubMed Central. Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database
Radiation therapy provides a clear benefit. A propensity-matched analysis of over a thousand patients found that radiation improved both overall survival and breast-cancer-specific survival, with the effect holding even in patients whose lymph nodes were negative.23PubMed Central. The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database Post-lumpectomy radiation improved survival in both early- and late-stage subgroups, while post-mastectomy radiation benefited patients with larger or node-positive tumors but did not reach significance for early-stage, node-negative cases.24PubMed. Metaplastic Breast Cancer: Practice Patterns, Outcomes, and the Role of Radiotherapy A single-institution analysis found that radiation improved five-year disease-free survival from roughly 39% to 64% and five-year local control from about 58% to 72%.25International Journal of Radiation Oncology, Biology, Physics. Metaplastic Breast Cancer: A Single-Institution Retrospective Analysis Given MBC’s high local recurrence rates, radiation appears especially valuable regardless of whether a patient has a lumpectomy or a mastectomy, though the benefit of post-mastectomy radiation in very early-stage cases remains less certain.
Why Chemotherapy Often Falls Short
Standard chemotherapy, the backbone of treatment for other triple-negative breast cancers, has a frustrating track record in MBC. Rates of complete pathological response to standard neoadjuvant chemotherapy range from only about 2% to 23%.26npj Breast Cancer. Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer One study of patients with metastatic or advanced disease found that none of those treated with anthracycline-, vinorelbine-, or cyclophosphamide-based regimens responded. A small fraction — about 18% — of those treated with taxane-based chemotherapy showed a partial response, but no one achieved a complete response.27PubMed. Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
This resistance likely stems from multiple factors. The EMT-driven biology discussed earlier tends to make cells more resilient to drug-induced death. The molecular heterogeneity within a single tumor means that a drug targeting one population of cells may leave another population untouched. And because MBC is triple-negative, the targeted hormonal and HER2-directed agents that improve outcomes in other breast cancers are not an option for most patients. Despite the poor response rates, chemotherapy is still commonly used, and in the large national database study, receipt of chemotherapy was associated with improved survival, suggesting some benefit even when the tumor does not visibly shrink on imaging.28PubMed Central. Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database
Emerging Therapies That Are Gaining Ground
The molecular vulnerabilities of MBC are finally being exploited by newer treatments. Three avenues show the most promise: drugs targeting the PI3K/AKT/mTOR pathway, immune checkpoint inhibitors, and antibody-drug conjugates.
Because PI3K pathway mutations are so common in MBC, inhibitors directed at this pathway have drawn early interest. In one study treating patients with metastatic MBC using PI3K/AKT/mTOR-directed therapies, the response rate was 25%, and the overall clinical benefit rate (including patients whose disease stabilized for at least six months) was 35%.29Annals of Oncology. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer One patient achieved a complete response lasting more than four years on a regimen that included a PI3K pathway inhibitor. In another case, a patient with metastatic MBC received the PI3K inhibitor buparlisib alongside paclitaxel and achieved a partial response lasting 17 months; when the PI3K drug was paused due to side effects, the tumor grew back, only to shrink again once it was resumed.30PubMed. PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study More recently, a patient with MBC arising in the context of a genetic syndrome associated with PTEN loss (which activates the same pathway) achieved disease stabilization lasting over three years on a novel AKT inhibitor called TAS-117, despite having progressed through multiple prior treatments.31PubMed Central. Remarkable response of metaplastic breast cancer to a novel targeted AKT inhibitor TAS-117 in a Cowden syndrome patient: a case report
Immune checkpoint inhibitors, particularly pembrolizumab, have produced some remarkable individual responses. Multiple case reports document partial or complete responses in patients with PD-L1–positive metastatic MBC treated with pembrolizumab alone or combined with chemotherapy.32PubMed Central. Complete Response of Triple-Negative Metaplastic Carcinoma of the Breast Using Pembrolizumab One patient with multiple lung metastases and a chest-wall mass experienced a near-complete response at 30 months on a pembrolizumab-based combination, with only mild residual activity on PET scan.33American Journal of Case Reports. Long-Term Response to Pembrolizumab in Metastatic Metaplastic Breast Carcinoma: A Case Report The high PD-L1 positivity rates in MBC provide a biological rationale for these successes, though it bears noting that these remain case reports and small series; large randomized trials specifically in MBC are still needed.
Antibody-drug conjugates represent another frontier. Sacituzumab govitecan, already approved for treatment-resistant triple-negative breast cancer, has shown early promise specifically in MBC. In one case, a patient who had failed anthracyclines, taxanes, platinum, and pembrolizumab achieved a complete metabolic response on sacituzumab govitecan, with maintained quality of life.34Annals of Case Reports. Case Report on Complete Response to Treatment of Metastatic Metaplastic Breast Cancer with Sacituzumab Govitecan These early signals need confirmation in larger studies, but for a cancer that has historically had few effective options beyond surgery and radiation, the expanding toolkit offers genuine hope.
Survival and Prognostic Factors
Overall, MBC carries a worse prognosis than the more common forms of invasive breast cancer. In one study, the two-year overall survival was 79% and the five-year overall survival was 69%.35PubMed Central. Metaplastic Breast Cancer: Characteristics and Survival Outcomes A study from India reported a broadly similar five-year overall survival of about 64%.36ecancer. Metaplastic carcinoma of the breast: real-world outcome from a tertiary cancer centre in India These numbers sit lower than the survival rates for breast cancer overall, reflecting MBC’s aggressive behavior and resistance to standard therapy.
Several factors predict worse outcomes. Advanced stage at diagnosis is the most obvious: stage III disease carried a roughly fivefold increased risk of death in one multivariable analysis. Poor functional status was also strongly associated with worse survival. Among sites of distant spread, lung and brain metastases were particularly ominous, with brain metastases carrying over an eightfold and lung metastases a dramatically higher risk of death.37PubMed Central. Metaplastic Breast Cancer: Characteristics and Survival Outcomes Lungs were the most common site of distant recurrence in multiple studies, followed by brain and bone.38ecancer. Metaplastic carcinoma of the breast: real-world outcome from a tertiary cancer centre in India
How MBC Differs From Ordinary Triple-Negative Breast Cancer
Because most metaplastic breast cancers test triple-negative, patients sometimes hear that their cancer is simply “triple-negative breast cancer” and are treated accordingly. That framing misses important distinctions. MBC and ordinary triple-negative invasive ductal carcinoma share the same receptor-negative status, but they diverge in genomics (far higher rates of PI3K mutations in MBC), in biology (EMT-driven tissue diversity), in chemosensitivity (markedly lower response rates in MBC), and in immune profile (higher PD-L1 expression on tumor cells). A patient whose MBC is lumped into the broader triple-negative category may receive standard chemotherapy without anyone considering PI3K-targeted agents or early immunotherapy, options that the molecular profile of MBC specifically supports.
The heterogeneity within MBC itself also means that treatment should be individualized where possible. A patient whose tumor has prominent squamous features and high PD-L1 expression may be a stronger candidate for immunotherapy than one with a predominantly chondroid tumor and a quieter immune microenvironment. Similarly, a tumor with a confirmed PIK3CA mutation may benefit from PI3K pathway inhibitors that would be irrelevant for a tumor driven by other genetic changes. Getting the pathologic subtype and molecular profile right is not just an academic exercise; it shapes which of the emerging therapies is most rational to try.
For patients navigating an MBC diagnosis, the rarity of the disease creates its own challenges. Many oncologists may see only a handful of cases in a career, and the evidence base is dominated by retrospective database analyses and case reports rather than large randomized trials. Seeking care at a center with experience in rare breast cancers, and asking about genomic testing to look for PI3K and other actionable mutations, can meaningfully influence treatment options. Clinical trials specifically enrolling MBC patients are few but growing in number, and participating in one may be the best route to accessing the targeted and immune therapies most suited to this unusual cancer’s biology.